BIT 7.50% 3.7¢ biotron limited

BIT Science Discussion, page-229

  1. 19,010 Posts.
    lightbulb Created with Sketch. 5792
    This paper might be of interest to the BIT investors [1] as it is an independent (if biased) assessment of BIT225. Two things were very interesting.

    1. BIT225 is thought to be too toxic to use. Quoting from the paper
    Two acylguanidine-containing compounds, HMA (Fig. 1A) and BIT-225 (Fig. 1B), are reported to inhibit HIV-1 replication; however, both display substantial in vitro toxicity, particularly to T cells (5, 6, 34, 35). We therefore sought to design an acylguanidine-based derivative with a reduced cytotoxic component. We observed that the heterocyclic amino-pyrazine core of HMA resembles the heterocyclic core of methotrexate, which is also cytotoxic (46), and speculated that the high nitrogen density in these cores might be a cause.

    2. HIV-1 resistance mutations to acylguanidines can be easily be isolated. The highly conserved structure of VPU does not seem to prevent HIV-1 resistance mutations arising in this protein.

    1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044834/
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
3.7¢
Change
-0.003(7.50%)
Mkt cap ! $33.38M
Open High Low Value Volume
3.8¢ 4.0¢ 3.7¢ $13.74K 361.7K

Buyers (Bids)

No. Vol. Price($)
1 421052 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 19000 1
View Market Depth
Last trade - 15.39pm 05/07/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.